AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.

Top 5 Upgrades:

• Oppenheimer upgraded Airbnb (ABNB) to Outperform from Perform with an $180 price target on the view that product initiatives around Hotels, RNPL, and AI search will generate durable revenue acceleration not fully reflected in Street estimates.
• Wedbush upgraded Trade Desk (TTD) to Neutral from Underperform with a $23 price target. The firm thinks the heightened competitive landscape and narrative pressure should be largely offset by spending tailwinds around the World Cup this summer and likely upside on political spending in the back-half.
• Cantor Fitzgerald upgraded GlobalFoundries (GFS) to Overweight from Neutral with a price target of $80, up from $50. Thursday’s investor day represents the first major capital markets event for GlobalFoundries since its post-IPO Capital Markets Day in 2022, and while the shares have “massively” underperformed since then, secular drivers are beginning to emerge in the story, the firm says.\
• Raymond James upgraded Acadia Healthcare (ACHC) to Strong Buy from Outperform with a price target of $39, up from $25. The company reported a solid Q1 beat and modestly raised its 2026 EBITDA and earnings outlook, the firm tells investors in a research note.
• H.C. Wainwright upgraded Celcuity (CELC) to Buy from Neutral with a price target of $165, up from $94. The firm believes gedatolisib could be a “game-changing” therapy for HR+/HER2- advanced breast cancer and could make Celcuity an acquisition target.

Top 5 Downgrades:

• HSBC downgraded AMD (AMD) to Hold from Buy with a price target of $340, up from $335. The firm sees limited upside to the company’s Q1 estimates, saying 2026 server upside will capped by foundry capacity constraints.
• Freedom Broker downgraded Alphabet (GOOGL) to Hold from Buy with a price target of $400, up from $365. The firm views the company’s Q1 results positively but downgrades the shares on valuation following the post-earnings rally.
• BofA downgraded Check Point (CHKP) to Neutral from Buy with a price target of $120, down from $260, following a “weak” Q1 report and FY26 growth outlook cut.
• Morgan Stanley downgraded Prudential (PRU) to Underweight from Equal Weight with a price target of $92, down from $106. Prudential is in a relatively worse position than peers given the multiple headwinds around Japan following the incremental sales suspension, macro, and earnings power, the firm tells investors.
• RBC Capital downgraded Safehold (SAFE) to Sector Perform from Outperform with a price target of $16, down from $18. Given an overhang from ongoing litigation related to the Park Hotels portfolio and uncertainty related to the 50th St asset, the firm sees limited upside potential for shares.

Top 5 Initiations:

• Evercore ISI resumed coverage of Becton Dickinson (BDX) with an Outperform rating and $180 price target. Becton Dickinson is in a transition year with the biosciences and diagnostics separation and a series of transitory headwinds “masking a more stable underlying growth profile,” the firm tells investors.
• Wells Fargo initiated coverage of BeOne Medicines (ONC) with an Overweight rating and $400 price target. The firm believes the company is well positioned in the $12B chronic lymphocytic leukemia market with “best-in-class options” for all patient segments.
• Scotiabank initiated coverage of Postal Realty Trust (PSTL) with an Outperform rating and $23 price target. Postal Realty Trust solely owns and acquires buildings leased to the U.S. Postal Service, which is an investment strategy “unique among U.S. REITs and difficult to replicate,” says the firm, which estimates a two-year AFFO per share compound annual growth rate at 7.4%, compared to 3.9% for Net Lease peers.
• Needham initiated coverage of Better Home & Finance (BETR) with a Buy rating and $53 price target.The firm believes Better Home’s “rapidly scaling” partnership channel positions the company for “outsized” growth even if the mortgage market recovers more slowly than expected.
• Rodman & Renshaw initiated coverage of Anavex (AVXL) with a Buy rating and $20 price target, implying 500% upside from the current share price. The firm says its thesis centers on blarcamesine, a once daily oral SIGMA1b receptor activator expected to enter a Phase 3 trial in early Alzheimer’s disease by the end of 2026.